DK1032672T3 - DNA19355-polypeptid, en tumornekrosefaktor-homolog - Google Patents

DNA19355-polypeptid, en tumornekrosefaktor-homolog

Info

Publication number
DK1032672T3
DK1032672T3 DK98958067T DK98958067T DK1032672T3 DK 1032672 T3 DK1032672 T3 DK 1032672T3 DK 98958067 T DK98958067 T DK 98958067T DK 98958067 T DK98958067 T DK 98958067T DK 1032672 T3 DK1032672 T3 DK 1032672T3
Authority
DK
Denmark
Prior art keywords
dna19355
necrosis factor
tumor necrosis
dna19355 polypeptide
factor homologue
Prior art date
Application number
DK98958067T
Other languages
English (en)
Inventor
Austin L Gurney
Scot A Marsters
Paul J Godowski
Avi J Ashkenazi
Robert Pitti
Kevin P Baker
Melanie R Mark
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1032672T3 publication Critical patent/DK1032672T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK98958067T 1997-11-18 1998-11-18 DNA19355-polypeptid, en tumornekrosefaktor-homolog DK1032672T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6563597P 1997-11-18 1997-11-18
US6966197P 1997-12-12 1997-12-12
PCT/US1998/024621 WO1999025834A1 (en) 1997-11-18 1998-11-18 Dna19355 polypeptide, a tumor necrosis factor homolog

Publications (1)

Publication Number Publication Date
DK1032672T3 true DK1032672T3 (da) 2009-04-27

Family

ID=26745805

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98958067T DK1032672T3 (da) 1997-11-18 1998-11-18 DNA19355-polypeptid, en tumornekrosefaktor-homolog

Country Status (12)

Country Link
US (4) US20020146389A1 (da)
EP (1) EP1032672B1 (da)
JP (2) JP4485049B2 (da)
AT (1) ATE419357T1 (da)
AU (1) AU760010B2 (da)
CA (1) CA2308365A1 (da)
DE (1) DE69840413D1 (da)
DK (1) DK1032672T3 (da)
ES (1) ES2320285T3 (da)
IL (1) IL135911A0 (da)
PT (1) PT1032672E (da)
WO (1) WO1999025834A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009327A2 (en) * 1999-07-28 2001-02-08 Genentech, Inc. Method of preventing the injury or death of retinal cells and treating ocular diseases
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
WO2001040464A1 (en) * 1999-11-30 2001-06-07 Genentech, Inc. Interleukin-1-receptor associated kinase-3 (irak3) and its use in promotion or inhibition of angiogenesis and cardiovascularization
DK1212417T3 (da) * 1999-06-02 2008-09-01 Genentech Inc Fremmelse eller inhibering af angiogenese og vaskularisering
ATE376837T1 (de) * 1999-07-12 2007-11-15 Genentech Inc Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen
DE10045591A1 (de) * 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
WO2003006058A1 (en) * 2001-07-12 2003-01-23 Wyeth Cd25+ differential markers and uses thereof
WO2003070763A1 (en) * 2001-08-16 2003-08-28 Human Genome Sciences, Inc. Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
EP1495756A4 (en) * 2002-04-08 2009-10-28 Takeda Pharmaceutical THERAPEUTIC AGENT FOR SEVERE SEPTIC STATE PREVENTION
AU2004244626A1 (en) * 2003-05-23 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
EP1660126A1 (en) * 2003-07-11 2006-05-31 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
EP1692318A4 (en) * 2003-12-02 2008-04-02 Genzyme Corp COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER
US20070065889A1 (en) * 2004-12-02 2007-03-22 Roberts Bruce L Compositions and methods to diagnose and treat lung cancer
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
PL3151921T3 (pl) 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
EP3304079B1 (en) 2015-06-03 2020-06-03 Bristol-Myers Squibb Company Anti-gitr antibodies for cancer diagnostics
MX2018006072A (es) 2015-11-19 2018-08-01 Squibb Bristol Myers Co Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
CA3027121A1 (en) 2016-06-10 2017-12-14 Regeneron Pharmaceuticals, Inc. Anti-gitr antibodies and uses thereof
WO2018213297A1 (en) 2017-05-16 2018-11-22 Bristol-Myers Squibb Company Treatment of cancer with anti-gitr agonist antibodies
MX2022010910A (es) 2020-03-06 2022-10-07 Regeneron Pharma Anticuerpos anti-gitr y usos de estos.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
CA2225378C (en) * 1995-06-29 2012-04-17 Immunex Corporation Cytokine that induces apoptosis
WO1998007880A1 (en) * 1996-08-16 1998-02-26 Human Genome Sciences, Inc. Human endokine alpha
US5998171A (en) * 1996-08-16 1999-12-07 Human Genome Sciences, Inc. Polynucleotides encoding human endokine alpha
US6406867B1 (en) * 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use

Also Published As

Publication number Publication date
IL135911A0 (en) 2001-05-20
US20060216270A1 (en) 2006-09-28
US20040234498A1 (en) 2004-11-25
DE69840413D1 (de) 2009-02-12
CA2308365A1 (en) 1999-05-27
AU760010B2 (en) 2003-05-08
EP1032672A1 (en) 2000-09-06
JP2001523459A (ja) 2001-11-27
ATE419357T1 (de) 2009-01-15
WO1999025834A1 (en) 1999-05-27
JP2010088448A (ja) 2010-04-22
US20020146389A1 (en) 2002-10-10
JP4485049B2 (ja) 2010-06-16
EP1032672B1 (en) 2008-12-31
AU1418099A (en) 1999-06-07
PT1032672E (pt) 2009-04-02
US20070072263A1 (en) 2007-03-29
ES2320285T3 (es) 2009-05-20

Similar Documents

Publication Publication Date Title
DE69840413D1 (de) Dna 19355 polypeptide, ein homolog des tumornekrosefaktors
CY1108175T1 (el) ΠΟΛΥΠΕΠΤΙΔΙΟ DcR3, ΟΜΟΛΟΓΟ TNFR
DE69930955D1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
DE69535719D1 (de) Fas-antigenbindender ligand
TW428026B (en) Bifunctional protein, preparation and use
FI101720B1 (fi) Synteettisen DNA:n konstruointi ja sen käyttö suurten polypeptidien synteesissä
DE69836092D1 (de) Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
EP0575546A4 (en) Prad1 cyclin and its cdna
YU47735B (sh) Postupak za sintezu biološki aktivnih polipeptida limfotoksina
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
DE68905633D1 (de) Markierer der t-zelle aktivierung.
BG100771A (bg) Хематопоетичен протеин и материали и методи за неговото получаване
ATE319818T1 (de) Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren
DE69737747D1 (de) Apo-2 ligand
PT770088E (pt) Nova citoquina designada lerk-5
NL990034I2 (nl) DNA dat codeert voor humane tumor necrosis faktor en humane tumor necrosis faktor polypeptide.
ATE414775T1 (de) Polypeptide mit prolyldipeptidylaminopeptidase- aktivität und dafür kodierende nukleinsäuren
ATE450603T1 (de) Polypeptide mit verzweigungsenzym-aktivität und für diese kodierende nukleinsäuren
DK0804558T3 (da) Tripeptidylaminopeptidase
ATE358725T1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
ATE424459T1 (de) Apo-3 ligand
ES2141249T3 (es) Procedimiento para la identificacion de celulas humanas y animales que presentan la capacidad para una proliferacion ilimitada o para una formacion de tumores.
DE69903559D1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
ATE236983T1 (de) Durch zelldichte stimulierte protein-tyrosin- phosphatasen